Abstract | OBJECTIVE: METHODS: One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. RESULTS: CONCLUSION:
|
Authors | John H Stone, Janet T Holbrook, Matthew A Marriott, Andrea K Tibbs, Lourdes P Sejismundo, Y-I Min, Ulrich Specks, Peter A Merkel, Robert Spiera, John C Davis, E William St Clair, W Joseph McCune, Steven R Ytterberg, Nancy B Allen, Gary S Hoffman, Wegener's Granulomatosis Etanercept Trial Research Group |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 54
Issue 5
Pg. 1608-18
(May 2006)
ISSN: 0004-3591 [Print] United States |
PMID | 16646004
(Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- Etanercept
|
Topics |
- Aged
- Clinical Trials as Topic
- Etanercept
- Female
- Granulomatosis with Polyangiitis
(drug therapy)
- Humans
- Immunoglobulin G
(adverse effects)
- Male
- Middle Aged
- Neoplasms
(chemically induced)
- Prospective Studies
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|